The absorbed radiation dose to human organs has been estimated, following intravenous administration of (67)Ga-labelled adrenocorticotrophic hormone (ACTH) using distribution data from injected normal rats. Four rats were sacrificed at exact time intervals and the percentage of injected dose per gram of each organ was measured by direct counting from rat data. The Medical Internal Radiation Dose formulation was applied to extrapolate from rat to human and to project the absorbed radiation dose for various organs in a human. From rat data, it is estimated that a 185-MBq injection of (67)Ga-diethylenetriaminepentaacetic acid-ACTH into a human might result in an estimated absorbed dose of 2.22 mGy to the whole body; the highest absorbed dose was in the bladder wall with 82.1 mGy and the organs that received the next highest doses were the lungs 31.8, liver 22.6 and spleen 8.72 mGy. These results suggest that it should be possible to perform early imaging of the lung anomalies.
The biodistribution of 67Ga-cDTPA-GnRH in rats showed high breast uptake and low muscle and blood uptake. These results suggest that it should be possible to perform early imaging of the breast anomalies and GnRH receptors indicating potential malignant lesions.
In this study, 177 Lu-(4-{[(bis(phosphonomethyl))-carbamoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl) acetic acid ( 177 Lu-BPAMD) was successfully prepared. The quality control, partition coefficient, hydroxyapatite binding assay and stability of the complex were determined. For better comparison, biodistribution patterns of 177 Lu-BPAMD and 177 Lu-EDTMP complexes were compared in same animal model. 177 Lu-BPAMD was prepared with high radiochemical purity ([93 %) and specific activity of 534 GBq/mmol at the optimal conditions. Comparative study between 177 Lu-BPAMD and 177 Lu-EDTMP indicated higher bone uptake and lesser accumulation in the other organs for 177 Lu-BPAMD. 177 Lu-BPAMD can be considered as a promising agent for bone pain palliation in the near future.
Electrical properties of the cells play a key role in biological processes. Intermediate frequencies of electrical fields influence the cells proliferation without heat generation and electrical stimulation. Silver nanoparticle (SNP) as a metallic agent can change the electrical characteristics of the cells. We study the effect of low voltages at an intermediate frequency (300 kHz) on a human breast adenocarcinoma cell line (MCF7) in the presence of SNPs. At first, cell toxicity of SNPs was determined at different concentrations. Then three different voltages were applied to the cells for 15 min, both in the presence and absence of SNPs. The treatments efficiency was evaluated by MTT assay. The results showed that the intermediate frequency-low voltages with SNPs not only provide an additive efficacy on cytotoxicity, but also a synergism was observed between these factors. By increasing the voltage from 3 to 9 V, a rising synergistic rate was observed. It seems that the synergistic effect between SNPs and the 300 kHz low voltages can inhibit cell proliferation and/or increases cell death of MCF-7, and hence increases treatment efficiency of SNPs, effectively.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.